Dr Reddy's Labs

how big is Dr Reddy's Labs?

As of Jun 06, Dr Reddy's Laboratories Ltd has a market capitalization of 110,231.55 Cr, with recent net sales of 32,643.90 Cr and net profit of 5,655.10 Cr over the last four quarters. Shareholder's funds are 28,254.80 Cr, and total assets amount to 37,806.00 Cr as of Mar'24.

Market Cap: As of Jun 06, Dr Reddy's Laboratories Ltd has a market capitalization of 110,231.55 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 32,643.90 Cr, and the sum of Net Profit is 5,655.10 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the reporting period of Mar'24. The Shareholder's Funds amount to 28,254.80 Cr, and the Total Assets are 37,806.00 Cr.

When is the next results date for Dr Reddy's Labs?

No Upcoming Board Meetings

What is the bonus history of the Dr Reddy's Labs?

Dr. Reddy's Laboratories issued a 1:1 bonus on August 28, 2006, allowing shareholders to double their holdings by receiving an additional share for each share owned, with the record date set for August 29, 2006.

Dr. Reddy's Laboratories has a bonus history that includes a notable 1:1 bonus issue announced on August 28, 2006. The record date for this bonus was August 29, 2006. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about the company or its financials, feel free to ask!

Has Dr Reddy's Labs declared dividend?

Yes, Dr Reddy's Laboratories has declared an 800% dividend, amounting to ₹40 per share, with an ex-date of July 16, 2024. The company has demonstrated strong total returns across various periods, with a total return of 15.2% over the past year.

Dr Reddy's Laboratories Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 40<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.62%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.26%, with no dividend return, resulting in a total return of 5.26%.<BR><BR>Over the past year, the price return was 11.89%, the dividend return was 3.31%, leading to a total return of 15.2%.<BR><BR>In the 2-year period, the price return was 42.35%, the dividend return was 8.21%, culminating in a total return of 50.56%.<BR><BR>For the last 3 years, the price return was 53.12%, with a dividend return of 12.94%, resulting in a total return of 66.06%.<BR><BR>In the 4-year timeframe, the price return was 25.6%, the dividend return was 12.49%, giving a total return of 38.09%.<BR><BR>Lastly, over the past 5 years, the price return was 63.89%, with a dividend return of 20.41%, leading to a total return of 84.3%.<BR><BR>Overall, Dr Reddy's Laboratories has declared a substantial dividend while also showing strong total returns across multiple periods, indicating a positive financial performance for the company.

Who are the peers of the Dr Reddy's Labs?

Dr Reddy's Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci, Lupin, Abbott India, and Aurobindo Pharma. In terms of performance, Divi's Lab leads with a 1-year return of 49.58%, while Dr Reddy's Labs has a return of -5.19%.

Peers: The peers of Dr Reddy's Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci., Lupin, Abbott India, and Aurobindo Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Aurobindo Pharma, while Average management risk is found at Lupin and Glenmark Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Torrent Pharma, and Aurobindo Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and Aurobindo Pharma, while good capital structure is found at Torrent Pharma and Lupin, and Glenmark Pharma has average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 49.58%, while Zydus Lifesci. has the lowest at -18.37%, with Dr Reddy's Labs showing a 1-year return of -5.19%, which is higher than Zydus Lifesci. but lower than Divi's Lab. Additionally, Zydus Lifesci., Lupin, and Aurobindo Pharma have negative six-month returns.

Who are in the management team of Dr Reddy's Labs?

As of March 2022, the management team of Dr Reddy's Labs includes G V Prasad (Co-Chairman & Managing Director), K Satish Reddy (Executive Chairman), and several independent directors, including Kalpana Morparia and Leo Puri, among others. This team is responsible for the company's strategic direction and governance.

As of March 2022, the management team of Dr Reddy's Labs includes the following individuals:<BR><BR>1. G V Prasad - Co-Chairman & Managing Director<BR>2. K Satish Reddy - Executive Chairman<BR>3. Kalpana Morparia - Independent Director<BR>4. Shikha Sanjaya Sharma - Independent Director<BR>5. Leo Puri - Independent Director<BR>6. K P Krishnan - Independent Director<BR>7. Pennv Wan - Independent Director<BR>8. K Randhir Singh - Company Secretary & Compliance Officer<BR>9. Arun M. Kumar - Independent Director<BR>10. Claudio Albrecht - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

What does Dr Reddy's Labs do?

Dr Reddy's Laboratories Limited is a global pharmaceutical company that offers affordable and innovative medicines, with a market cap of INR 104,919 Cr and a net profit of INR 15,933 Cr as of March 2025. Key metrics include a P/E ratio of 19.00 and a dividend yield of 1.27%.

Overview:<BR>Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company that provides affordable and innovative medicines, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Dr Reddy's Laboratories was incorporated in the year N/A. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 85,284 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 15,933 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: INR 104,919 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.27%<BR>- Debt Equity: -0.03<BR>- Return on Equity: 16.86%<BR>- Price to Book: 3.13<BR><BR>Contact Details:<BR>Address: 8-2-337 Road No 3, Banjara Hills Hyderabad Telangana : 500034<BR>Tel: 91-40-49002900<BR>Email: shares@drreddys.com<BR>Website: http://www.drreddys.com

Who are the top shareholders of the Dr Reddy's Labs?

The top shareholders of Dr Reddy's Labs include promoter G V Prasad with 11.52%, J P Morgan Chase Bank Na as the largest public shareholder at 11.54%, mutual funds holding 12.89%, foreign institutional investors at 25.75%, and individual investors with approximately 8.2%.

The top shareholders of Dr Reddy's Labs include several key players. The majority shareholders are the promoters, with G V Prasad being the promoter with the highest holding at 11.52%. In the public domain, J P Morgan Chase Bank Na holds a significant stake of 11.54%, making it the highest public shareholder. Additionally, mutual funds collectively hold 12.89% through 38 schemes, while foreign institutional investors (FIIs) account for 25.75% with 799 FIIs involved. Individual investors hold around 8.2% of the shares.

Are Dr Reddy's Labs latest results good or bad?

Dr. Reddy's Laboratories reported a net profit of ₹1,340.80 crores for Q2 FY26, a 7.30% year-on-year increase, and net sales grew by 9.83%. However, profitability concerns arise from a 5.44% quarter-on-quarter decline in net profit and reduced operating margins, indicating challenges in cost management.

Dr. Reddy's Laboratories' latest results present a mixed picture. On one hand, the company achieved a net profit of ₹1,340.80 crores for Q2 FY26, which is a 7.30% increase year-on-year. Additionally, net sales reached ₹8,828.30 crores, reflecting a 9.83% growth compared to the same quarter last year and a 2.99% increase from the previous quarter.<BR><BR>However, there are notable concerns regarding profitability. The net profit decreased by 5.44% quarter-on-quarter, and the operating margin fell to 22.77% from 25.36% in the previous quarter, indicating increased cost pressures. The profit after tax (PAT) margin also declined to 15.07% from 16.45%, highlighting challenges in maintaining profitability amidst rising operational costs.<BR><BR>Overall, while revenue growth is a positive aspect, the decline in margins and net profit suggests that the company is facing significant headwinds in terms of cost management and pricing pressures in the pharmaceutical sector. Investors may want to keep an eye on how the company addresses these margin compression issues in the coming quarters.

Is Dr Reddy's Labs overvalued or undervalued?

As of October 27, 2025, Dr Reddy's Labs is fairly valued with a PE ratio of 18.57, lower than its peers like Sun Pharma and Divi's Lab, despite recent underperformance compared to the Sensex.

As of 27 October 2025, Dr Reddy's Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 18.57, an EV to EBITDA ratio of 11.31, and a Price to Book Value of 0.30, which indicate a reasonable valuation compared to its peers.<BR><BR>In comparison to its peers, Dr Reddy's Labs has a lower PE ratio than Sun Pharma (35.43) and Divi's Lab (74.62), both of which are classified as expensive. Additionally, it is on par with Cipla (PE of 23.74) and Zydus Lifesciences (PE of 21.52), which are also attractive. Despite a recent underperformance relative to the Sensex over the past year, where Dr Reddy's returned -1.40% compared to the Sensex's 6.77%, the valuation metrics suggest that the stock is currently fairly valued in the market.

Is Dr Reddy's Labs technically bullish or bearish?

As of November 28, 2025, Dr Reddy's Labs shows a mildly bullish trend based on daily moving averages and weekly Dow Theory, despite mixed signals from weekly MACD and KST indicators.

As of 28 November 2025, the technical trend for Dr Reddy's Labs has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are bearish, suggesting mixed signals. The weekly Dow Theory shows a mildly bullish trend, but the monthly indicators remain mostly bearish or neutral. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory, despite the bearish signals from MACD and KST on the weekly time frame.

How has been the historical performance of Dr Reddy's Labs?

Dr Reddy's Labs has shown consistent growth from Mar'20 to Mar'25, with net sales increasing from 17,517 Cr to 32,643.90 Cr and profit after tax rising from 1,969.90 Cr to 5,703.50 Cr. The company has maintained positive cash flow and expanded its total assets significantly, reflecting strong financial health.

Answer:<BR>The historical performance of Dr Reddy's Labs shows a consistent growth trajectory in net sales, with figures rising from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Total operating income has mirrored this trend, increasing from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Operating profit (PBDIT) has also seen significant growth, climbing from 3,091.00 Cr in Mar'20 to 9,644.40 Cr in Mar'25, although the operating profit margin has fluctuated, peaking at 28.42% in Mar'24 before dropping to 26.26% in Mar'25. Profit before tax has increased from 1,829.60 Cr in Mar'20 to 7,657.80 Cr in Mar'25, while profit after tax has risen from 1,969.90 Cr to 5,703.50 Cr over the same period. The company's total assets have grown from 22,005.40 Cr in Mar'20 to 47,594.10 Cr in Mar'25, reflecting a strong balance sheet, while total liabilities have also increased, from 22,005.40 Cr to 47,594.10 Cr. Cash flow from operating activities has shown a positive trend, increasing from 2,984.00 Cr in Mar'20 to 4,642.00 Cr in Mar'25, contributing to a net cash inflow of 748.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Reddy's Labs has demonstrated robust growth in net sales, which rose from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25, indicating a strong demand for its products. The total operating income followed suit, reflecting the same upward trend. Operating profit (PBDIT) has significantly increased, reaching 9,644.40 Cr in Mar'25, although the operating profit margin experienced some volatility. Profit before tax surged to 7,657.80 Cr, while profit after tax reached 5,703.50 Cr, showcasing the company's improving profitability. The total assets of Dr Reddy's Labs expanded considerably, reflecting its growth strategy, while total liabilities also increased, indicating a corresponding rise in financial obligations. The cash flow from operating activities has remained positive, contributing to a net cash inflow, which further underscores the company's solid financial health and operational efficiency.

Should I buy, sell or hold Dr Reddys Laboratories Ltd?

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 17-Mar, Dr Reddys Laboratories Ltd's stock price is rising to 1,281.55, indicating a potential shift in market sentiment after a recent decline. Strong fundamentals, institutional backing, and a positive return over the past year support this upward trend.

As of 17-Mar, Dr Reddys Laboratories Ltd's stock price is rising, currently at 1,281.55, with a change of 6.5 (0.51%) upward. This increase follows a trend reversal after three consecutive days of decline, indicating a potential shift in market sentiment. The stock's performance today is in line with its sector, suggesting that it is not an isolated movement but part of broader market dynamics.<BR><BR>Despite a recent drop in investor participation, with delivery volume falling by 30.34% against the 5-day average, the stock remains liquid enough for trading, indicating that there is still interest among investors. The company's strong fundamentals, characterized by low debt and healthy long-term growth rates in net sales and operating profit, support its valuation. With a low Debt to Equity ratio of 0.01 and a Return on Equity of 15.78%, Dr Reddys Laboratories Ltd demonstrates high profitability, which can attract investors looking for stable returns.<BR><BR>Additionally, the stock's performance over the past year, generating an 11.47% return, combined with high institutional holdings at 63.64%, suggests confidence from larger investors who typically have more resources to analyze the company's fundamentals. This institutional backing can further bolster the stock's price as it indicates a belief in the company's long-term potential. Overall, these factors contribute to the stock's current upward movement.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 18-Mar, Dr Reddys Laboratories Ltd's stock price is 1,287.00, reflecting a slight increase of 0.3% after two days of gains. Despite a recent weekly decline, the stock shows positive long-term fundamentals and a fair valuation, though decreased investor participation indicates cautious sentiment.

As of 18-Mar, Dr Reddys Laboratories Ltd is experiencing a slight rise in its stock price, currently at 1,287.00, with an increase of 3.9 (0.3%). This upward movement follows a trend where the stock has gained for the last two days, resulting in a total return of 0.94% during this period. <BR><BR>Despite a recent decline of 2.90% over the past week, the stock has shown resilience with a positive return of 0.48% over the last month and a notable increase of 10.50% over the past year. The company's strong long-term fundamentals, characterized by a low debt-to-equity ratio of 0.01 times and a healthy return on equity averaging 15.78%, contribute to its attractiveness as an investment. Additionally, the stock is trading at a fair value compared to its peers, which supports its valuation.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 51.22% against the five-day average. This decrease in trading activity could indicate a cautious sentiment among investors, despite the stock's recent gains. Overall, the combination of positive long-term growth prospects and recent price movements suggests that Dr Reddys Laboratories Ltd is currently rising, albeit with some caution in market participation.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 19-Mar, Dr Reddys Laboratories Ltd's stock price is at 1,275.00, down 1.49% after a trend reversal. Despite strong long-term fundamentals, declining investor participation and sector performance are contributing to the stock's current decline.

As of 19-Mar, Dr Reddys Laboratories Ltd's stock price is falling, currently at 1,275.00, which reflects a decrease of 19.25 or 1.49%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed the sector, despite outperforming the broader market by 0.66% today. Additionally, the stock touched an intraday low of Rs 1267.2, indicating a significant drop of 2.09% during the trading session.<BR><BR>Investor participation appears to be declining, as evidenced by a delivery volume of 5.25 lacs on 18 March, which has decreased by 45.34% compared to the 5-day average. Furthermore, the overall performance of the Pharmaceuticals & Drugs sector has also fallen by 2.11%, contributing to the downward pressure on Dr Reddys Laboratories Ltd's stock price.<BR><BR>Despite these negative indicators, the company maintains strong long-term fundamentals, including low debt and healthy growth rates in net sales and operating profit. However, the immediate market conditions and reduced investor activity are likely influencing the current decline in stock price.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 20-Mar, Dr Reddys Laboratories Ltd's stock price has risen to 1,295.00, reflecting a 1.64% increase, driven by strong fundamentals, positive relative performance against the Sensex, and favorable technical indicators. The company's low debt-to-equity ratio and high institutional holdings further enhance market confidence.

As of 20-Mar, Dr Reddys Laboratories Ltd is experiencing a rise in its stock price, currently at 1,295.00, which reflects an increase of 20.95 (1.64%). This upward movement can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has shown positive performance relative to the benchmark Sensex over various periods. For instance, over the past week, Dr Reddys Laboratories Ltd has increased by 0.15%, while the Sensex has slightly decreased by 0.04%. Additionally, the stock has outperformed the Sensex over the past month, gaining 1.15% compared to the Sensex's decline of 10.00%. Year-to-date, the stock has risen by 1.88%, while the Sensex has fallen by 12.54%. This relative strength indicates a favorable market perception of the company compared to broader market trends.<BR><BR>Moreover, the stock's performance today aligns with sector trends, and it reached an intraday high of Rs 1306.3, marking a 2.53% increase. The stock is also trading above its 5-day, 50-day, 100-day, and 200-day moving averages, which is typically a positive technical indicator. <BR><BR>The company’s strong fundamentals further support the stock's rise. Dr Reddys Laboratories Ltd has a low debt-to-equity ratio of 0.01, indicating financial stability, and has demonstrated healthy long-term growth with net sales increasing at an annual rate of 13.12% and operating profit at 18.90%. The return on equity (ROE) stands at an average of 15.78%, showcasing high profitability per unit of shareholders' funds. <BR><BR>Additionally, the stock is perceived to be attractively valued, trading at a fair price-to-book ratio compared to its peers. The high institutional holdings at 63.64% suggest confidence from larger investors, who typically have more resources to analyze the company's fundamentals.<BR><BR>In summary, the combination of positive relative performance, strong fundamentals, and favorable technical indicators contributes to the rising stock price of Dr Reddys Laboratories Ltd.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 23-Mar, Dr Reddys Laboratories Ltd's stock price is at 1,252.55, down 3.57%, reflecting a bearish trend influenced by poor financial results and overall sector performance. The stock is trading below all key moving averages, and despite increased delivery volume, negative investor sentiment persists.

As of 23-Mar, Dr Reddys Laboratories Ltd's stock price is falling, currently at 1,252.55, which reflects a decrease of 46.4 points or 3.57%. This decline is consistent with the overall performance of the pharmaceuticals and drugs sector, which has fallen by 3.62%. The stock has also touched an intraday low of Rs 1246.5, indicating a significant drop of 4.04% during the trading day.<BR><BR>In terms of moving averages, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Additionally, while there has been a notable increase in delivery volume, rising by 256.27% against the 5-day average, this does not offset the negative price movement.<BR><BR>The company's recent financial results have also contributed to the stock's decline. Negative results reported for December 25 indicate a drop in return on capital employed (ROCE) to 18.75%, and a significant fall in profit before tax (PBT) and profit after tax (PAT) compared to previous quarters, with decreases of 18.3% and 16.2% respectively. These disappointing financial metrics have likely influenced investor sentiment negatively, leading to the current downward trend in the stock price.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 24-Mar, Dr Reddys Laboratories Ltd's stock price is rising to 1,260.40, driven by increased investor participation and solid fundamentals despite some past challenges. The stock remains above its moving averages, indicating positive short-term momentum.

As of 24-Mar, Dr Reddys Laboratories Ltd's stock price is rising, currently at 1,260.40, with a change of 7.85 (0.63%) upward. This increase can be attributed to several factors. Firstly, the stock has shown a significant rise in investor participation, with a delivery volume of 14.28 lacs on 23 March, which is an increase of 46.43% compared to the 5-day average. This suggests a growing interest among investors.<BR><BR>Additionally, the stock has touched an intraday high of Rs 1279.5, reflecting a 2.15% increase during the trading day. Despite underperforming its sector by -0.49%, the stock remains higher than its 50-day and 100-day moving averages, indicating some positive momentum in the short term.<BR><BR>From a fundamental perspective, Dr Reddys Laboratories Ltd is characterized by low debt and strong long-term growth, with net sales growing at an annual rate of 13.12% and operating profit at 18.90%. The company also boasts a low debt-to-equity ratio of 0.01 times and a return on equity of 15.78%, which signifies high profitability. Furthermore, the stock is trading at a fair valuation compared to its peers, with a price-to-book value of 2.9.<BR><BR>However, it is important to note that the company has faced challenges, such as negative results in December 2025, including a significant drop in profit after tax and the lowest return on capital employed. Despite these negatives, the current rise in stock price can be attributed to increased investor interest and the company's solid fundamentals, which may be encouraging investors to buy into the stock.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 25-Mar, Dr Reddys Laboratories Ltd's stock price has risen to 1,301.90, reflecting a 3.36% increase due to strong market performance, positive fundamentals, and heightened investor interest. The stock is trading above its moving averages and shows significant growth in net sales and operating profit.

As of 25-Mar, Dr Reddys Laboratories Ltd is experiencing a rise in its stock price, currently at 1,301.90, reflecting an increase of 42.3 points or 3.36%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.47% today and has shown a consecutive gain over the last two days, accumulating a total return of 3.94% during this period. Additionally, the stock reached an intraday high of Rs 1310, marking a 4% increase.<BR><BR>The company is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which indicates a strong bullish trend. Furthermore, there has been a significant increase in investor participation, with delivery volume rising by 86.27% compared to the 5-day average, suggesting heightened interest and confidence among investors.<BR><BR>From a fundamental perspective, Dr Reddys Laboratories Ltd is characterized by low debt levels and strong long-term growth, with net sales growing at an annual rate of 13.12% and operating profit at 18.90%. The company maintains a low debt-to-equity ratio of 0.01 times and has generated a return on equity of 15.78%, indicating high profitability. The stock is also viewed as attractively valued, trading at a price-to-book value of 3, which is fair compared to its peers.<BR><BR>Overall, the combination of positive market performance, strong fundamentals, and increased investor interest contributes to the rising stock price of Dr Reddys Laboratories Ltd.

Which are the latest news on Dr Reddy's Labs?